Assessing Sertoli cell function without surgery depends on two key biomarkers: Anti-Müllerian Hormone (AMH) and Inhibin B. These glycoproteins are secreted directly by Sertoli cells, making their serum concentrations a direct, non-invasive reflection of testicular tissue integrity and functional capacity. In pediatric and adolescent endocrinology, measuring both markers has become a cornerstone for differentiating conditions like anorchia, gonadal dysgenesis, and cryptorchidism from more benign causes of non-palpable testes, effectively replacing the need for invasive Leydig cell stimulation testing in many clinical scenarios.
The core clinical value of AMH and Inhibin B lies in their ability to directly report on the presence and functional health of testicular parenchyma. Undetectable or extremely low levels in a boy with non-palpable testes strongly suggest absent or severely damaged tissue, while a normal AMH level can confirm retained testes and even help pinpoint disorders like androgen insensitivity.
The Biological Basis: Why Sertoli Cell Markers Matter
The traditional approach to evaluating testicular Leydig cell function relied on human chorionic gonadotropin (hCG) stimulation tests to measure testosterone response. However, that method is invasive, time-consuming, and does not directly assess the seminiferous tubules where sperm production occurs. Sertoli cells line those tubules and sustain germ cell development; their products provide a more holistic view of testicular health.
AMH as a Window into Immature Sertoli Cell Function
In males, AMH is produced at high levels by fetal and pre-pubertal Sertoli cells. It causes the regression of Müllerian ducts during embryonic development. Postnatally, serum AMH remains markedly elevated until puberty.
When testosterone rises during puberty, it downregulates AMH production. This creates a powerful diagnostic window: in pre-pubertal boys, high AMH is a robust signal of functioning Sertoli cells. If AMH is undetectable or profoundly low, it indicates either the absence of testicular tissue (anorchia) or severe, global testicular damage (e.g., in gonadal dysgenesis).
Inhibin B as the Conformation of Tubular Integrity
Inhibin B is a dimeric glycoprotein that provides negative feedback on pituitary FSH secretion. It is secreted by Sertoli cells in response to FSH and reflects both the number and functional integrity of those cells, as well as the overall state of spermatogenesis.
Low Inhibin B values correlate with impaired spermatogenesis and Sertoli cell dysfunction. In conjunction with AMH, it provides an extra layer of confirmation: both markers will be essentially absent in anorchic boys, while in partial testicular insufficiency, one may be disproportionately affected.
Core Clinical Applications in Pediatric Andrology
The diagnostic strength of these biomarkers is most pronounced in the differential diagnosis of disorders of sexual development and cryptorchidism. The clinical question often shifts from “Is there testicular tissue?” to “How healthy is it, and can we spare the patient an invasive workup?”
Distinguishing Anorchia from Cryptorchidism
In a boy with bilateral non-palpable testes, the critical decision tree is whether surgical exploration is warranted or if the testes are simply retractile. Undetectable AMH and extremely low Inhibin B make anorchia highly likely, allowing clinicians to avoid the morbidity and cost of diagnostic laparoscopy.
A detectable, normal-range AMH level, on the other hand, indicates the presence of functioning testicular tissue. This can guide imaging or a limited surgical procedure to locate retained testes, with a much higher pre-test probability of surgical success.
Identifying Gonadal Dysgenesis and Disorders of Sexual Development
In infants with ambiguous genitalia or a 46,XY karyotype, an absent or blunted Sertoli cell response (low AMH) points toward gonadal dysgenesis or streak gonads. This is particularly valuable because testosterone production may be partially preserved in some forms, making hCG tests misleading.
Conversely, an elevated AMH can be a critical finding. It is characteristic of partial androgen insensitivity syndrome (PAIS) , where the androgen receptor is resistant to testosterone but Sertoli cells remain responsive to FSH and continue to secrete high levels of AMH. This paradoxical elevation helps differentiate PAIS from other causes of undervirilization.
Evaluating Delayed Puberty
In a teenager with constitutional delay of growth and puberty, AMH will be appropriately elevated for bone age and then gradually decline as puberty begins. Persistently high AMH beyond the expected age of puberty onset may point to hypogonadotropic hypogonadism—the Sertoli cells are intact and ready, but lack the gonadotropin drive to mature.
Understanding the Trade-offs and Diagnostic Limitations
While AMH and Inhibin B are powerful, their interpretation demands nuance. Treating them as simple “yes/no” tests can lead to misdiagnosis.
Age-Dependent Reference Ranges Are Non-Negotiable
AMH is high during infancy, peaks around 4–8 years, and then declines rapidly with pubertal testosterone. A level that is normal for a 3-year-old would be concerning in a 13-year-old. Laboratories must provide rigidly established age- and puberty-stage-specific reference intervals. Without these, the clinical utility collapses.
Assay Standardization Remains a Hurdle
Historically, there has been no universal calibrator for AMH assays. Different manufacturers’ kits can yield significantly different absolute values. This introduces variability when comparing results across labs or when publishing clinical thresholds. For Inhibin B, inter-assay precision at extremely low concentrations remains a technical challenge. Clinicians must know the assay platform used and interpret trends within that platform’s frame.
Limited Utility After Sertoli Cell Maturation
Once a male reaches late puberty, AMH normally drops to very low levels. At that point, measuring AMH to assess Sertoli cell integrity is less informative—a low value is expected and no longer implies pathology. Inhibin B becomes the more useful marker, as it continues to reflect spermatogenic capacity, but its diagnostic specificity for tissue presence diminishes if the patient has already established a low baseline.
The Snare of Sample Handling
AMH is relatively stable, but Inhibin B can be susceptible to pre-analytical degradation. Hemolysis, delayed serum separation, or repeated freeze-thaw cycles can artifactually lower concentrations. For clinicians relying on undetectable levels to diagnose anorchia and avoid surgery, a false-low from poor sample handling has serious consequences.
Making the Right Choice for Your Diagnostic Panel
As a clinical laboratory or diagnostic manufacturer building a male reproductive health menu, the integration of AMH and Inhibin B should be targeted to specific patient populations and clinical questions.
- If your primary focus is assessing the presence of testicular tissue in pre-pubertal boys: Prioritize AMH as a first-line, single-sample, non-invasive marker, and ensure age-specific reference data are built into your reporting.
- If your primary focus is comprehensive evaluation of disorders of sexual development: Offer both AMH and Inhibin B together, because the combination identifies not just tissue presence but also Sertoli cell responsiveness and can differentiate PAIS through elevated AMH.
- If your primary focus is the transition to puberty and monitoring delayed puberty: Incorporate serial AMH measurements with emphasis on the expected decline over time, and pair with LH, FSH, and testosterone for a complete picture of the hypothalamic-pituitary-gonadal axis.
- If your primary focus is assay reagent development: Invest in high-purity monoclonal antibodies that ensure consistent epitope recognition across lots, and actively pursue alignment with emerging international reference preparations for AMH to address the standardization gap.
When correctly utilized with rigorous pre-analytical protocols and proper age-based interpretation, AMH and Inhibin B transform the evaluation of male testicular integrity from a surgical guessing game into a precise, biology-driven clinical dialogue.
Summary Table:
| Biomarker | Biological Source & Function | Key Clinical Applications | Diagnostic Significance |
|---|---|---|---|
| AMH (Anti-Müllerian Hormone) | Secreted at high levels by pre-pubertal Sertoli cells; regresses Müllerian ducts | Differentiating anorchia from cryptorchidism, evaluating PAIS, monitoring delayed puberty | Detectable levels confirm testicular tissue; undetectable levels signal anorchia or severe damage |
| Inhibin B | Dimeric glycoprotein secreted by Sertoli cells under pituitary FSH control | Assessing spermatogenic capacity and seminiferous tubule integrity | Correlates with germ cell development; low/absent levels confirm testicular insufficiency |
Advance Your Andrology & Reproductive Diagnostic Panels with CamelBio
Developing high-precision AMH and Inhibin B immunoassays requires exceptional reagent stability, low cross-reactivity, and stringent lot-to-lot consistency. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you need premium antibodies for assay development or technical guidance on overcoming standardization challenges, our expert team is dedicated to supporting your diagnostic innovation.
Contact CamelBio today to discover how we can elevate your immunoassay performance!